Navigation Links
Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
Date:9/18/2013

BLUE BELL, Pa., Sept. 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will be presenting an overview of the company at the Aegis Capital Corp. Healthcare Conference and BioCentury's 20th Annual NewsMakers in the Biotech Industry Conference. He will also be the invited speaker at the Town Hall Los Angeles meeting on Tuesday, September 24, 2013. In his speech titled, "Are We Prepared for the Next Pandemic Flu Virus? Is a New Universal Vaccine the Answer," Dr. Kim will discuss the potential devastating effects of an influenza pandemic and how medicine is working urgently to meet the next pandemic.

Aegis Capital Corp. Healthcare Conference

September 25-28, 2013
The Encore at Wynn Las Vegas
Las Vegas, NV

Inovio Presentation
Thursday, September 26, 2013
8:30 AM PT

BioCentury's 20th Annual NewsMakers in the Biotech Industry Conference

September 27, 2013
Millennium Broadway Hotel
New York, NY

Inovio Presentation
Friday, September 27, 2013
11:30 AM ET

A live and archived webcast of the NewsMakers presentation will be accessible on the homepage of Inovio's website under the webcast tab at www.inovio.com.

Town Hall Los Angeles

September 24, 2013
11:30 AM -1:30 PM PT
Millennium Biltmore Hotel
Los Angeles, CA

Individuals interested in attending may register online.

About Town Hall Los Angeles
Town Hall Los Angeles is recognized as one of the Top 10 Executive Leadership Forums. They invite one compelling and newsworthy speaker to their luncheon forum each month to present issues that affect Angelenos and provide a platform for the discussion of solutions from a nonpartisan point of view. The audience of the forum draws from the top business leaders across industries in the area.

About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended June 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Inc. (NASDAQ: IPXL ) today announced that it plans to ... Raymond James and Associates, 38 th Annual Institutional Investors Conference ... FL. Cowen and Company 37 th ... in Boston, MA. Barclays Global ... Miami, FL. Individuals may listen to ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The global ... CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. ... from 2016 to 2027. The market is estimated at $816m in ... ... to discover how you can exploit the future business opportunities emerging ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology:
(Date:2/27/2017)... Houston, Texas (PRWEB) , ... February 27, 2017 ... ... leader in the alternative health care industry, announces Chris Brandl as its New ... has brought vision and purpose to corporations throughout his career. He began his ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long ... company involved in the underground testing of nuclear weapons. Years later, when her co-workers ... of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies ...
(Date:2/27/2017)... ... 26, 2017 , ... Miro is the ultimate smart media center that offers ... movies, TV shows and much more apps for user exploration. Its innovative acoustic design ... of 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
(Date:2/26/2017)... ... 2017 , ... Today, A' Design Awards & Competition has ... Design Awards. , The 7th A' Social Design Award is open for ... with realized projects and conceptual works. , The first phase of the International ...
Breaking Medicine News(10 mins):